The United States announced new plans to impose escalating tariffs on all imported generic drugs beginning in August 2028, with rates set to increase to 100 percent within the first year and potentially doubling thereafter. The move, announced by President Donald Trump, aims to restore the domestic production of generic pharmaceuticals—a key component of his administration’s broader trade protection strategy recently expanded to include patented and innovative drugs.

Despite the strict tariff proposals, analysts argue that China’s advancement in the pharmaceutical sector is largely impervious to these measures. They highlight that China’s dominant position lies not in finished generic drugs, but rather upstream in the production of active pharmaceutical ingredients (APIs), where it supplies roughly 40 percent of the global market according to government data. This upstream dominance remains critical in the global pharmaceutical supply chain.

Bruce Liu, senior partner at consulting firm Simon-Kucher, noted that shifting generic drug manufacturing to the United States would likely more than double production costs due to increased expenses in supply chains, manufacturing, and waste management, resulting in higher prices for American consumers. Zhang Jianlin, head of China healthcare research at Nomura, also emphasized that generic drug sales to the U.S. constitute a relatively small portion of Chinese pharmaceutical companies’ overall revenues, suggesting that the impact of the tariffs would be limited in the near term.

India currently stands as the largest buyer of China-produced APIs and is the main supplier of generic drugs to the U.S. market, supplying approximately 40 percent of generics sold in the country, according to the U.S. ambassador to India and data from the China Chamber of Commerce for Import and Export of Medicines and Health Products.

China’s pharmaceutical industry has increasingly shifted focus from generics to innovative drug development, a transition underpinned by a surge in out-licensing deals and supportive government policies. An HSBC report noted that the value of out-licensing agreements by Chinese biotech firms reached $136 billion in 2025—nearly twice the value of China’s electric vehicle exports. Cross-border deals for innovative drugs hit a record $110 billion in the first half of 2026, with further growth expected.

Trade restrictions have extended beyond tariffs. U.S. lawmakers have introduced regulatory and investment limitations targeting China’s biotechnology sector, citing national security and ethical concerns. The U.S. House Select Committee on China has launched an investigation into five major American pharmaceutical corporations—Bristol Myers Squibb, Eli Lilly, Merck, AbbVie, and Pfizer—questioning their clinical trials conducted in military hospitals and regions such as Xinjiang. In May, the committee also recommended a ban on American investments in Chinese biotechnology under the Comprehensive Outbound Investment National Security Act of 2025.

However, some industry experts, including Tony Ren of Macquarie Capital, argue that these measures have faced resistance and predict a strong year for China’s healthcare sector in 2026 despite mounting regulatory pressures. Analysts maintain that China’s established role in the global pharmaceutical supply chain remains highly resilient amid evolving U.S. trade policy efforts.